Q3 EPS Forecast for Arcus Biosciences Reduced by Analyst

Key Points

• HC Wainwright has reduced its Q3 2025 earnings per share (EPS) estimate for Arcus Biosciences from ($1.24) to ($1.32), reflecting a more pessimistic outlook for the company.
• Several analysts have adjusted their target prices for Arcus Biosciences, with Morgan Stanley lowering it from $24.00 to $22.00 while Barclays significantly cut their price target from $29.00 to $14.00.
• Arcus Biosciences reported a revenue increase of 310.3% year-over-year, with Q2 earnings at ($1.11) EPS, surpassing consensus estimates of ($1.14) EPS by $0.03.

Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) - Analysts at HC Wainwright reduced their Q3 2025 earnings estimates for shares of Arcus Biosciences in a research report issued to clients and investors on Thursday, August 7th. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings of ($1.32) per share for the quarter, down from their previous estimate of ($1.24). The consensus estimate for Arcus Biosciences' current full-year earnings is ($3.15) per share. HC Wainwright also issued estimates for Arcus Biosciences' Q4 2025 earnings at ($1.19) EPS, FY2025 earnings at ($3.83) EPS, FY2026 earnings at ($4.13) EPS, FY2027 earnings at ($4.32) EPS, FY2028 earnings at ($3.04) EPS and FY2029 earnings at ($1.87) EPS.

Other equities research analysts also recently issued reports about the stock. Wedbush reissued an "outperform" rating and issued a $33.00 price objective on shares of Arcus Biosciences in a research report on Wednesday, May 7th. Morgan Stanley dropped their target price on Arcus Biosciences from $24.00 to $22.00 and set an "overweight" rating on the stock in a report on Friday, May 9th. Barclays dropped their price objective on Arcus Biosciences from $29.00 to $14.00 and set an "overweight" rating on the stock in a report on Wednesday, April 23rd. The Goldman Sachs Group dropped their price target on shares of Arcus Biosciences from $15.00 to $13.00 and set a "neutral" rating on the stock in a research note on Thursday, May 8th. Finally, Wall Street Zen raised Arcus Biosciences from a "strong sell" rating to a "hold" rating in a report on Saturday. Three investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to MarketBeat, Arcus Biosciences currently has an average rating of "Moderate Buy" and an average price target of $21.14.

Arcus Biosciences Stock Up 5.8%

Shares of RCUS stock traded up $0.53 during trading hours on Monday, reaching $9.69. 995,373 shares of the stock were exchanged, compared to its average volume of 1,037,341. The business's fifty day moving average is $9.15 and its two-hundred day moving average is $9.38. The company has a debt-to-equity ratio of 0.18, a current ratio of 4.50 and a quick ratio of 4.50. Arcus Biosciences has a 12-month low of $6.50 and a 12-month high of $18.98. The firm has a market capitalization of $1.03 billion, a P/E ratio of -3.06 and a beta of 0.89.

Arcus Biosciences (NYSE:RCUS - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported ($1.11) earnings per share for the quarter, beating analysts' consensus estimates of ($1.14) by $0.03. Arcus Biosciences had a negative net margin of 109.56% and a negative return on equity of 55.96%. The firm had revenue of $160.00 million during the quarter, compared to analysts' expectations of $32.86 million. During the same quarter in the previous year, the business posted ($1.02) earnings per share. The business's quarterly revenue was up 310.3% compared to the same quarter last year.

Hedge Funds Weigh In On Arcus Biosciences

A number of hedge funds and other institutional investors have recently bought and sold shares of RCUS. Gilead Sciences Inc. purchased a new position in Arcus Biosciences in the 4th quarter valued at $447,610,000. Woodline Partners LP boosted its holdings in Arcus Biosciences by 45.5% in the 1st quarter. Woodline Partners LP now owns 5,127,304 shares of the company's stock valued at $40,249,000 after purchasing an additional 1,603,367 shares in the last quarter. Boxer Capital Management LLC purchased a new stake in Arcus Biosciences in the 4th quarter valued at approximately $23,857,000. Vanguard Group Inc. boosted its holdings in Arcus Biosciences by 24.1% in the 1st quarter. Vanguard Group Inc. now owns 6,687,800 shares of the company's stock valued at $52,499,000 after purchasing an additional 1,298,584 shares in the last quarter. Finally, RA Capital Management L.P. acquired a new stake in shares of Arcus Biosciences in the 1st quarter valued at approximately $8,920,000. 92.89% of the stock is currently owned by hedge funds and other institutional investors.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.